RHYTHM PHARMACEUTICALS, INC. - Common Stock (RYTM)
CUSIP: 76243J105
Q2 2025 13F Holders as of 30 Jun 2025
- Type / Class
- Equity / Common Stock
- Shares outstanding
- 67,341,788
- Total 13F shares
- 66,543,505
- Share change
- +1,932,077
- Total reported value
- $4,204,958,379
- Put/Call ratio
- 274%
- Price per share
- $63.19
- Number of holders
- 225
- Value change
- +$136,584,141
- Number of buys
- 125
- Number of sells
- 105
Quarterly Holders Quick Answers
What is CUSIP 76243J105?
CUSIP 76243J105 identifies RYTM - RHYTHM PHARMACEUTICALS, INC. - Common Stock in SEC institutional holdings data.
Need full ownership history?
Open the full security ownership history page.
Next holder-history checks
These links keep the next click tied to holder verification, nearby quarters, or outside-13F ownership context.
- Back to full security ownership history for the broader multi-quarter picture.
- Latest 13F filings for newly reported positions across managers.
- Latest Schedule 13D/13G reports for ownership changes outside the 13F cadence.
- SEC investors directory for manager drilldown.
Explore More Reporting Periods
Jump to adjacent filing periods for faster comparison and easier crawl discovery.
Recent filing periods for CUSIP 76243J105:
Top shareholders of RYTM - RHYTHM PHARMACEUTICALS, INC. - Common Stock (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Ownership % is shown only when it is directly reported or safely comparable across share classes.
Methodology: rows are grouped by holder and ranked by the holder's primary source value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
| Holder | Source | Role / Reporting | Ownership % | Shares | Holdings Value | 12M Net Δ | As of | Details |
|---|---|---|---|---|---|---|---|---|
| BlackRock, Inc. |
13F
13D/G
|
Company |
6.9%
from 13D/G
|
6,854,755
|
$363,096,374 | — | 31 Mar 2025 | |
| BAKER BROS. ADVISORS LP |
13D/G
13F
|
Company |
8.9%
|
5,604,483
|
$360,984,750 | $0 | 31 Mar 2025 | |
| RA CAPITAL MANAGEMENT, L.P. |
13F
|
Company |
9%
|
6,084,412
|
$322,291,304 | — | 31 Mar 2025 | |
| PRIMECAP MANAGEMENT CO/CA/ |
13F
|
Company |
8.6%
|
5,787,322
|
$306,554,446 | — | 31 Mar 2025 | |
| PERCEPTIVE ADVISORS LLC |
13D/G
13F
|
Company |
6.8%
|
4,423,441
|
$284,913,835 | $0 | 31 Mar 2025 | |
| VANGUARD GROUP INC |
13F
|
Company |
5.1%
|
3,444,926
|
$182,477,729 | — | 31 Mar 2025 | |
| NEA Management Company, LLC |
13F
|
Company |
4.3%
|
2,909,956
|
$154,140,369 | — | 31 Mar 2025 | |
| GOLDMAN SACHS GROUP INC |
13D/G
13F
|
THE GOLDMAN SACHS GROUP, INC. · Company |
3%
|
1,818,932
|
$117,157,406 | $0 | 31 Dec 2024 | |
| STATE STREET CORP |
13F
|
Company |
2.9%
|
1,970,733
|
$104,389,727 | — | 31 Mar 2025 | |
| JANUS HENDERSON GROUP PLC |
13F
|
Company |
2.5%
|
1,655,350
|
$90,747,654 | — | 31 Mar 2025 | |
| FMR LLC |
13F
|
Company |
2.5%
|
1,688,375
|
$89,433,248 | — | 31 Mar 2025 | |
| FEDERATED HERMES, INC. |
13F
|
Company |
2.4%
|
1,591,871
|
$84,321,407 | — | 31 Mar 2025 | |
| DRIEHAUS CAPITAL MANAGEMENT LLC |
13F
|
Company |
2.2%
|
1,458,022
|
$77,231,425 | — | 31 Mar 2025 | |
| WESTFIELD CAPITAL MANAGEMENT CO LP |
13F
|
Company |
2%
|
1,341,092
|
$71,037,643 | — | 31 Mar 2025 | |
| GEODE CAPITAL MANAGEMENT, LLC |
13F
|
Company |
1.9%
|
1,287,168
|
$68,196,935 | — | 31 Mar 2025 | |
| PRICE T ROWE ASSOCIATES INC /MD/ |
13F
|
Company |
1.8%
|
1,199,053
|
$63,515,000 | — | 31 Mar 2025 | |
| Checkpoint Capital L.P. |
13F
|
Company |
1.3%
|
907,240
|
$48,056,503 | — | 31 Mar 2025 | |
| Rock Springs Capital Management LP |
13F
|
Company |
1.2%
|
834,188
|
$44,186,938 | — | 31 Mar 2025 | |
| ALKEON CAPITAL MANAGEMENT LLC |
13F
|
Company |
1.2%
|
817,700
|
$43,313,569 | — | 31 Mar 2025 | |
| Frazier Life Sciences Management, L.P. |
13F
|
Company |
1%
|
678,760
|
$35,953,917 | — | 31 Mar 2025 | |
| Hood River Capital Management LLC |
13F
|
Company |
0.98%
|
659,431
|
$34,930,060 | — | 31 Mar 2025 | |
| LOOMIS SAYLES & CO L P |
13F
|
Company |
0.9%
|
605,764
|
$32,087,000 | — | 31 Mar 2025 | |
| NORTHERN TRUST CORP |
13F
|
Company |
0.8%
|
536,206
|
$28,402,833 | — | 31 Mar 2025 | |
| MARSHALL WACE, LLP |
13F
|
Company |
0.79%
|
535,103
|
$28,344,405 | — | 31 Mar 2025 | |
| MORGAN STANLEY |
13F
|
Company |
0.75%
|
504,049
|
$26,699,494 | — | 31 Mar 2025 | |
| Polar Capital Holdings Plc |
13F
|
Company |
0.74%
|
500,000
|
$26,485,000 | — | 31 Mar 2025 | |
| Opaleye Management Inc. |
13F
|
Company |
0.73%
|
490,000
|
$25,955,300 | — | 31 Mar 2025 | |
| Sofinnova Investments, Inc. |
13F
|
Company |
0.66%
|
446,839
|
$23,669,062 | — | 31 Mar 2025 | |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC |
13F
|
Company |
0.66%
|
445,429
|
$23,594,374 | — | 31 Mar 2025 | |
| VOLORIDGE INVESTMENT MANAGEMENT, LLC |
13F
|
Company |
0.63%
|
422,868
|
$22,399,318 | — | 31 Mar 2025 | |
| ORBIMED ADVISORS LLC |
13F
|
Company |
0.56%
|
380,000
|
$20,128,600 | — | 31 Mar 2025 | |
| BALYASNY ASSET MANAGEMENT L.P. |
13F
|
Company |
0.53%
|
355,712
|
$18,842,065 | — | 31 Mar 2025 | |
| SILVERARC CAPITAL MANAGEMENT, LLC |
13F
|
Company |
0.5%
|
337,605
|
$17,882,937 | — | 31 Mar 2025 | |
| FRANKLIN RESOURCES INC |
13F
|
Company |
0.48%
|
326,160
|
$17,276,695 | — | 31 Mar 2025 | |
| S.c.a. Candriam |
13F
|
Individual |
0.43%
|
291,469
|
$15,439,113 | — | 31 Mar 2025 | |
| Siren, L.L.C. |
13F
|
Individual |
0.41%
|
277,533
|
$14,700,923 | — | 31 Mar 2025 | |
| UBS Group AG |
13F
|
Company |
0.4%
|
272,108
|
$14,413,561 | — | 31 Mar 2025 | |
| Invesco Ltd. |
13F
|
Company |
0.39%
|
261,902
|
$13,872,949 | — | 31 Mar 2025 | |
| Pictet Asset Management Holding SA |
13F
|
Company |
0.39%
|
259,346
|
$13,853,913 | — | 31 Mar 2025 | |
| COMERICA BANK |
13F
|
Company |
0.36%
|
244,754
|
$12,964,619 | — | 31 Mar 2025 | |
| MILLENNIUM MANAGEMENT LLC |
13F
|
Company |
0.32%
|
217,379
|
$11,514,566 | — | 31 Mar 2025 | |
| Qube Research & Technologies Ltd |
13F
|
Company |
0.32%
|
216,193
|
$11,451,743 | — | 31 Mar 2025 | |
| Cubist Systematic Strategies, LLC |
13F
|
Company |
0.26%
|
173,822
|
$9,207,355 | — | 31 Mar 2025 | |
| Cormorant Asset Management, LP |
13F
|
Company |
0.22%
|
150,000
|
$7,945,500 | — | 31 Mar 2025 | |
| Nuveen, LLC |
13F
|
Company |
0.22%
|
147,301
|
$7,802,534 | — | 31 Mar 2025 | |
| Bank of New York Mellon Corp |
13F
|
Company |
0.22%
|
146,585
|
$7,764,607 | — | 31 Mar 2025 | |
| JPMORGAN CHASE & CO |
13F
|
Company |
0.21%
|
143,640
|
$7,608,611 | — | 31 Mar 2025 | |
| PANAGORA ASSET MANAGEMENT INC |
13F
|
Company |
0.21%
|
141,162
|
$7,477,351 | — | 31 Mar 2025 | |
| Samsara BioCapital, LLC |
13F
|
Company |
0.21%
|
138,118
|
$7,316,110 | — | 31 Mar 2025 | |
| LORD, ABBETT & CO. LLC |
13F
|
Company |
0.2%
|
135,360
|
$7,170,000 | — | 31 Mar 2025 |
Institutional Holders of RHYTHM PHARMACEUTICALS, INC. - Common Stock (RYTM) as of Q2 2025
As of 30 Jun 2025,
RHYTHM PHARMACEUTICALS, INC. - Common Stock (RYTM) was held by
225 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
66,543,505 shares.
The largest 10 holders included
BlackRock, Inc., BAKER BROS. ADVISORS LP, RA CAPITAL MANAGEMENT, L.P., PRIMECAP MANAGEMENT CO/CA/, VANGUARD GROUP INC, NEA Management Company, LLC, PERCEPTIVE ADVISORS LLC, FMR LLC, STATE STREET CORP, and GOLDMAN SACHS GROUP INC.
This page lists
224
institutional shareholders reporting positions in this security
for the Q2 2025 filing period.
| Investor | Option | Weight % | Change % | Value $ | * Price | Shares | Share Change | Activity | Report Period |
|---|
Compare Q2 2025 vs Q1 2025 Across Filers
Q1 2025 holders
226
Q2 2025 holders
225
Holder diff
-1
| Investor | Q1 2025 Shares | Q2 2025 Shares | Share Diff | Share Chg % | Q1 2025 Value $ | Q2 2025 Value $ | Value Diff $ | Value Chg % |
|---|
Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).
Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.
An asterisk sign (*) next to the price indicates that the price is likely invalid.